United Therapeutics Corporation (UTHR)

Market Cap	21.68B +40.5%
Revenue (ttm)	3.18B +10.6%
Net Income	1.33B +11.7%
EPS	27.86 +13.1%
Shares Out	43.06M
PE Ratio	18.08
Forward PE	18.00
Dividend	n/a
Ex-Dividend Date	n/a

Volume	764,140
Open	530.01
Previous Close	535.10
Day's Range	496.44 - 532.25
52-Week Range	266.98 - 537.19
Beta	0.86
Analysts	Buy
Price Target	520.00 (+3.26%)
Earnings Date	Feb 25, 2026

About UTHR

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of tre...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jun 17, 1999
• Employees: 1,400
• Stock Exchange: NASDAQ
• Ticker Symbol: UTHR
• Website: https://www.unither.com

Financial Performance

In 2025, United Therapeutics's revenue was $3.18 billion, an increase of 10.61% compared to the previous year's $2.88 billion. Earnings were $1.33 billion, an increase of 11.68%.

Analyst Summary

According to 13 analysts, the average rating for UTHR stock is "Buy." The 12-month stock price target is $520.0, which is an increase of 3.26% from the latest price.

Price Target

$520.0

(3.26% upside)

Analyst Consensus: Buy